A 46-year-old 
Introduction

Autoimmune hepatitis (AIH) has been shown to be associated with a number of other autoimmune diseases (1, 2). Patients with AIH may be at increased risk for developing systemic connective tissue disease (CTD) (3). While AIH and CTD are different entities, the boundary between the two disorders can be indistinct (3). Pulmonary arterial hypertension (PAH) occurs in a variety of conditions including CTD and some rheumatic diseases (4). PAH is characterized by progressive obliteration of small vessels in the pulmonary vascular bed leading to permanently increased pulmonary vascular resistance and elevated pulmonary artery pressure, which may result in right heart failure and premature death. However, treatment options for patients with PAH have evolved to help prolong their survival and improve their quality of life. Early identification of PAH and its underlying or concurrent pathology is important for treatment outcome (5). We report a rare case of AIH with PAH, which was diagnosed from investigating multiple serological markers.
Case Report
A 46-year-old woman was admitted to our hospital with a low-grade fever and arthralgia. The (6) (Fig. 1) (Fig. 4) . She was maintained on prednisolone at 2 mg/day. E c h o c a r d i o g r a p h y . a : A p a r a s t e r n a l s h o r t a x i s v i e w r e v e a l s a d i l a t e d , h y p e r t r o p h i c  r i g h t v e n t r i c l e a n d s e p t a l f l a t t e n i n g . b : Do p p l e r e c h o c a r d i o g r a p h y s h o ws a d i l a t e d r i g h t v e n t r i c l .
F i g u r e 1 . Hi s t o l o g i c a l f i n d i n g s o f l i v e r b i o p s y . L i v e r b i o p s y s h o ws mo d e r a t e t o s e v e r e p o r t a l i nf l a mma t i o n i n f i l t r a t e d b y l y mp h o c y t e s a n d p l a s ma c e l l s ( a ) , i n t e r f a c e h e p a t i t i s ( b ) ( a r r o w) , p o r t a l f i b r o s i s wi t h n o d u l a r f o r ma t i o n ( c ) a n d ( d ) r o s e t t e a r r a n g e me n t o f h e p a t o c y t e s ( a r r o w) i n p e r i p o rt a l z o n e . ( a , b , d : He ma t o x y l i n a n d E o s i n s t a i n i n g ; c : Ma s s o n -t r i c h r o me s t a i n ) . Ma g n i f i c a t i o n f o r a
r i s o n o f t h e s e t wo p h o t o g r a p h s s h o ws t h a t t h e e n d o t h e l i a l wa l l s o f s e v e r a l v e s s e l s a r e p o s i t i v e f o r D2 -4 0 ( s t a r s a n d f i n e a r r o ws i n F i g . 3 a ) b u t a r e n e g a t i v e f o r CD3 4 ( F i g . 3 b ) . T h e s e a r e l y mp h a t i c c a p i l l a r i e s . On t h e o t h e r h a n d , s e v e r a l v e s s e l s a r e p o s i t i v e f o r CD3 4 ( a r r o wh e a d s a n d b o l d a r r o ws i n F i g . 3 b ) b u t n e g a t i v e f o r D2 -4 0 ( F i g . 3 a ) . T h e s e a r e b l o o d v e s s e l s . I n t h i s c a s e d il a t e d l y mp h a t i c v e s s e l s a r e o b s e r v e d . P : p o r t a l v e i n . L y m: l y mp h a t i c c a p i l l a r y . B l a c k a r r o wh e a d d e n o t e s p o r t a l v e i n . B l a c k b o l d a r r o w d e n o t e s b l o o d c a p i l l a r y , a r t e r i o l e o r v e n u l e . B l a c k f i n e a r r o w d e n o t e s l y mp h a t i c c a p i l l a r y . S t a r d e n o t e s d i l a t e d l y mp h a t i c c a p i l l a r i e s . He ma t o x y l i n c o u n t e r s t a i n i n g .
F i g u r e 4 . Cl i n i c a l c o u r s e . I t a l i c s r e p r e s e n t me d i c a t i o n s . ANA: a n t i -n u c l e a r a n t i b o d y ; F u n c t i o n a l S t a t u s ( WHO) : Wo r l d He a l t h Or g a n i z a t i o n Cl a s s i f i c a t i o n o f F u n c t i o n a l S t a t u s o f P a t i e n t s wi t h P u lmo n a r y Hy p e r t e n s i o n ; MP AP : me a n p u l mo n a r y a r t e r y p r e s s u r e ; P VR: p u l mo n a r y v a s c u l a r r e s i st a n c e
U/mL (normal: <15.0). Other assays including anti-ds-
Pulmonary arterial hypertension (PAH) is the most ominous complication of collagen vascular diseases (4). The patient was judged to be class II according to the WHO Classification of Functional Status of Patients With Pulmonary
Hypertension (8) (Fig. 4) . (8) . All these conditions manifest similar pathological obstructive changes of the pulmonary microcirculation, suggesting shared pathobiological processes across the disease spectrum of PAH (9) . The pathology of the pulmonary artery has been described in a case of fatal pulmonary arterial hypertension with noncirrhotic portal fibrosis. Autopsy revealed classical plexogenic pulmonary arteriopathy in the lung pathological finding (10) . (11, 12) . In the present case, gastrointestinal fiberscope showed no esophageal and gastric varices, and CT scan depicted no gastro-renal shunt; therefore, the etiology of PAH was unlikely to be associated with portal hypertension. Unfortunately hemodynamic study of liver-portal circulation was not undertaken.
Discussion
We report a rare case of AIH with PAH from which we obtained multiple immunologic data. PAH includes idiopathic PAH (IPAH) and pulmonary hypertension associated with various conditions such as CTD, congenital systemicto-pulmonary shunts, portal hypertension and human immunodeficiency virus (HIV) infection
Recently, portopulmonary hypertension (PPH) is defined as the development of pulmonary arterial hypertension complicated by portal hypertension with or without advanced hepatic disease. Despite the rarity of PPH (2% of the patients with portal hypertension), its clinical implications are significant
Since the presence of PAH has been extensively described in the course of various CTDs (4), we investigated the association of PAH with CTDs. In a recent study on communitybased rheumatology practices in the US, the prevalence of PAH was 13.3% in patients with systemic sclerosis and mixed connective tissue disease as analyzed by echocardiography (13) . These data were confirmed in a British study that adopted hemodynamic confirmation by right heart catheterization using a diagnostic algorithm, which found a prevalence of 12% in patients with systemic sclerosis (14) . PAH appears to be less commonly associated with systemic lupus erythematosus; however, well-controlled prospective trials are lacking and retrospective studies reported a prevalence of up to 14% as assessed by echocardiography (15 (16) .
